Information Provided By:
Fly News Breaks for June 16, 2015
AAVL
Jun 16, 2015 | 08:53 EDT
Cowen said the sell-off in Avalanche Biotechnologies following the release of its wet-AMD data is overdone, as the drug was safe and active. The firm noted that given its slight improvement over the control group its role in the treatment of wet AMD will need to be defined by future studies. Cowen maintained its Outperform rating and $55 price target on Avalanche Biotech shares.
News For AAVL From the Last 2 Days
There are no results for your query AAVL